ONC201 in Pediatric H3 K27M Gliomas

Status Active, not recruiting

Clinical Trial Summary

This is a multicenter, open-label, seven arm, dose escalation, phase I study of oral ONC201 in pediatric patients with newly diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) and recurrent/refractory H3 K27M gliomas. Arm A will define the RP2D for single agent ONC201 in pediatric patients with glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory) and have completed at least one line of prior therapy. This will allow for recurrent patients and also patients who have not yet recurred, but have completed radiation and will inevitably recur based on prior clinical experience and the literature. Arm B will define the RP2D for ONC201 in combination with radiation in pediatric patients with newly diagnosed DIPG. Arm C will determine intratumoral drug concentrations and biomarker expression in pediatric patients with midline gliomas. Arm D will determine H3 K27M DNA levels and drug concentrations in the CSF of pediatric H3 K27M-mutant glioma patients. Arm E will determine the RP2D for single agent ONC201 administered as a liquid formulation in Ora-Sweet to patients with DIPG and/or H3 K27M glioma. Arm F is a dose expansion cohort to confirm the safety and estimate the efficacy in recurrent H3 K27M-mutant glioma population at the RP2D. Arm G will define the RP2D for single agent ONC201 given on two consecutive days of each week in pediatric patients with glioma who are positive for the H3 K27M mutation and have completed at least one line of prior therapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03416530
Study type	Interventional
Source	Chimerix
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	January 29, 2018
Completion date	September 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01922076` - Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas	Phase 1
Recruiting	`NCT05476939` - Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0	Phase 3
Terminated	`NCT03330197` - A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG	Phase 1/Phase 2
Terminated	`NCT03690869` - REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma	Phase 1/Phase 2
Active, not recruiting	`NCT02992015` - Gemcitabine in Newly-Diagnosed Diffuse Intrinsic Pontine Glioma	Early Phase 1
Terminated	`NCT01182350` - Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)	Phase 2
Recruiting	`NCT04837547` - PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy	Phase 1
Active, not recruiting	`NCT04911621` - Adjuvant Dendritic Cell Immunotherapy for Pediatric Patients With High-grade Glioma or Diffuse Intrinsic Pontine Glioma	Phase 1/Phase 2
Not yet recruiting	`NCT06333899` - Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion	Early Phase 1
Completed	`NCT00879437` - Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma	Phase 2
Active, not recruiting	`NCT02420613` - Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma	Phase 1
Completed	`NCT03086616` - CED With Irinotecan Liposome Injection Using Real Time Imaging in Children With Diffuse Intrinsic Pontine Glioma (DIPG) (PNOC 009)	Phase 1
Recruiting	`NCT01837862` - A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas	Phase 1/Phase 2
Not yet recruiting	`NCT06093165` - RE-irradiation of Diffuse MIdline Glioma paTients	N/A
Withdrawn	`NCT03632317` - A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas	Phase 2
Completed	`NCT02502708` - Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors	Phase 1
Recruiting	`NCT02233049` - Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication	Phase 2
Completed	`NCT00996723` - Clinical Trial Evaluating the Combination of Vandetanib and Dasatinib During and After Radiation Therapy (RT) in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)	Phase 1
Recruiting	`NCT05009992` - Combination Therapy for the Treatment of Diffuse Midline Gliomas	Phase 2
Recruiting	`NCT04049669` - Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG	Phase 2